[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER

[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER (also known as DB07956 or PDB ligand 956) is an experimental small molecule inhibitor of the Hepatitis C Virus (HCV) NS3 protease. It is a peptidomimetic compound consisting of a Boc-protected valine residue linked to a 3-chloro-2-formylphenylcarbamoyl group. The aldehyde (formyl) moiety serves as an electrophilic trap that forms a reversible covalent hemiacetal adduct with the catalytic Ser139 residue of the NS3 protease. This compound has been primarily utilized as a structural biology tool to map the S1' and S2 pockets of the HCV NS3/4A protease complex, providing critical insights that informed the development of first-generation clinical protease inhibitors such as telaprevir and boceprevir. It was developed and studied by researchers at the Schering-Plough Research Institute.

Other names

tert-butyl [(1S)-1-{[(3-chloro-2-formylphenyl)amino]carbonyl}-2-methylpropyl]carbamateBoc-Val-2-amino-6-chlorobenzaldehyde derivativeBoc-Val2-amino-6-chlorobenzaldehyde derivativeBoc-Val 2-amino-6-chlorobenzaldehyde derivative